Discuss the data presented at EHA 2024 on the efficacy and safety of teclistimab in patients with relapsed/refractory multiple myeloma (RRMM) with high-risk features: a subgroup analysis of the phase 1/2 MajesTEC-1 study. (Abstract)
1. What was the objective of the subgroup analysis of this study?
2. How was this study designed/what methodology was used?
3. What results were presented?
  1. N=165
4. N=24 aged ≥75 years
5. N=20 ISS stage III
6. N=38 high-risk cytogenetics
7. N=28 extramedullary disease
8. N=18 bone marrow plasma cells
9. N=50 penta-drug refractory
  1. Median follow up ~30 months across subgroups
  2. Objective Response Rate (ORR)
  3. Median duration of response (mDOR)
  4. Safety

Related Content

Blood smear AML | image credit: Chansom Pantip - stock.adobe.com

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML

October 20th 2024

Article

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.

Screenshot of an interview with Courtney VanHouzen, PharmD

Making Cancer Care Easier With Community Bispecific Antibody Programs

October 15th 2024

Article

Allowing patients to stay in their homes to receive bispecific antibodies can make the whole cancer journey easier, explained Courtney VanHouzen, PharmD, of Cowell Family Cancer Center, Munson Healthcare.

Thomas Jefferson | Image: Thomas Jefferson University

Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy

October 13th 2024

Article

Health disparities word cloud | Image Credit: Colored Lights-stock.adobe.com

Delays in Myeloma Oral Therapy Linked to Race, Age

October 11th 2024

Article

Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) medication and time from initial diagnosis to receipt of any treatment for MM.

Surbhi Sidana, MD, MBBS, Stanford University

Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care

October 2nd 2024

Article

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant.

Multiple myeloma | Image credit: freshidea - stock.adobe.com

Varied Types, Levels of Support Needed for Patients With Multiple Myeloma

September 20th 2024

Article

Information on the disease and treatments, assistance with insurance, and transportation are among the types of support needed by patients with multiple myeloma to improve outcomes and overall burden.